David N Church

24PUBLICATIONS
162CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markersCancer diagnosisTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Oct 27, 2026
CD4+ T cell-licensed CD8+ T cells are required for immunotherapy response in MHC-I negative MMRd cancer.

|Feb 13, 2026
Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types.

Andrew Everall, Avraam Tapinos, Aliah Hawari

|Jan 09, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Timothy Iveson, Mark P Saunders, Caroline Kelly

|Jan 08, 2026
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev

|Aug 29, 2025
Spatiotemporal Immune Landscape and Long-term Immune Memory in POLE-Mutant Endometrial Cancer at the Single-Cell Level.

Koen Brummel, Marta Requesens, Nienke van Rooij

|Aug 25, 2025
Replication-associated mechanisms contribute to an increased CpG > TpG mutation burden in mismatch repair-deficient cancers.

Joseph C Ward, Ignacio Soriano, Steve Thorn

Pageof 4

Frequent Collaborators

5 joint publications

Tjalling Bosse

4 joint publications

Viktor Koelzer

3 joint publications

Alicia León-Castillo

3 joint publications

Hans W Nijman